An international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.
Mitiglinide is a drug for the treatment of type 2 diabetes.
Acefylline (INN), also known as acetyloxytheophylline, is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation etanautine to help offset diphenhydramine induced drowsiness.
Lufuradom (INN) is a drug and benzodiazepine derivative which, unlike other benzodiazepines, is described as an analgesic. Similarly to its analogue tifluadom, it was never marketed.
Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.
Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.
Morforex, also referable to as N-morpholinoethylamphetamine, is an anorectic which was never marketed.
Picilorex is an anorectic which is no longer marketed. It is a monoamine reuptake inhibitor.
Acridorex is an amphetamine which was investigated as an anorectic but does not appear to have ever been marketed.
Oxifentorex (INN) is an amphetamine described as an anorectic which does not appear to have ever been marketed.
Fenisorex is an amphetamine-like anorectic drug which does not appear to have ever been marketed.
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Remeglurant is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.
Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease.
Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
Duvortuxizumab (INN) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.
Letolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
Andecaliximab is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
